Efficacy of guselkumab compared with adalimumab for psoriasis: a meta-analysis of randomized controlled studies
作者全名:"Fu, Hongyi; Guo, Jing"
作者地址:"[Fu, Hongyi] Chongqing Med Univ, Dept Med Cosmetol Ctr, Branch 1, Affilliated Hosp 1, Chongqing, Peoples R China; [Guo, Jing] Youyang Peoples Hosp, Dept Dermatol, Chongqing, Peoples R China"
通信作者:"Guo, J (通讯作者),Youyang Peoples Hosp, Dept Dermatol, Chongqing, Peoples R China."
来源:POSTEPY DERMATOLOGII I ALERGOLOGII
ESI学科分类:CLINICAL MEDICINE
WOS号:WOS:000891776500021
JCR分区:Q4
影响因子:1.4
年份:2022
卷号:39
期号:5
开始页:953
结束页:958
文献类型:Article
关键词:guselkumab; adalimumab; psoriasis; efficacy; randomized controlled trials
摘要:"Introduction: The efficacy of guselkumab versus adalimumab for psoriasis remains controversial. Aim: We conducted a systematic review and meta-analysis to explore the influence of guselkumab versus adalim-umab on treatment efficacy for psoriasis. Material and methods: We have searched PubMed, Embase, Web of Science, EBSCO, and Cochrane library data-bases for randomized controlled trials (RCTs) published until March 2021 and assessing the efficacy and safety of guselkumab versus adalimumab for psoriasis. This meta-analysis was performed using the random-effects model. Results: Three RCTs were included in the meta-analysis. Overall, compared with adalimumab for psoriasis, gusel-kumab was associated with improved PASI 100 (OR = 2.18; 95% CI: 1.47 to 3.23; p = 0.0001), PASI 90 (OR = 2.63; 95% CI: 2.11 to 3.27; p < 0.00001), PASI 75 (OR = 3.10; 95% CI: 2.35 to 4.08; p < 0.00001) and PGA 0/1 (OR = 2.04; 95% CI: 1.26 to 3.31; p = 0.004), as well as decreased DLQI (SMD = -0.24; 95% CI: -0.34 to -0.13; p < 0.00001). In addition, gusel-kumab resulted in higher DLQI score 0/1 (OR = 1.88; 95% CI: 1.51 to 2.33; p < 0.00001) than adalimumab. Conclusions: Guselkumab showed better efficacy than adalimumab for psoriasis."
基金机构:
基金资助正文: